Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

3(20%)

Results Posted

33%(2 trials)

Terminated

1(7%)

Phase Distribution

Ph early_phase_1

Ph phase_1

40%

Ph not_applicable

Ph phase_2

47%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution15 total trials

Early Phase 1First-in-human

1(6.7%)

Phase 1Safety & dosage

6(40.0%)

Phase 2Efficacy & side effects

7(46.7%)

N/ANon-phased studies

1(6.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Completed(6)

Terminated(3)

Detailed Status

Completed6

Not yet recruiting3

Recruiting2

Withdrawn2

Active, not recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (6.7%)

Phase 16 (40.0%)

Phase 27 (46.7%)

N/A1 (6.7%)

Trials by Status

not_yet_recruiting320%

recruiting213%

withdrawn213%

completed640%

active_not_recruiting17%

terminated17%

Recent Activity

3 active trials

Showing 5 of 15

completedphase_2

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

NCT00113282

recruitingphase_1

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780

not_yet_recruitingphase_1

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

NCT07443020

recruitingearly_phase_1

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

NCT06318871

withdrawnphase_1

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

NCT06190249

View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials

NCT00113282Phase 2

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

Completed

NCT05681780Phase 1

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Recruiting

NCT07443020Phase 1

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Not Yet Recruiting

NCT06318871Early Phase 1

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Recruiting

NCT06190249Phase 1

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Withdrawn

NCT05975554Not Applicable

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Active Not Recruiting

NCT06971913Phase 2

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Not Yet Recruiting

NCT04241601Phase 2

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY

Completed

NCT05810792Phase 2

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

Not Yet Recruiting

NCT03215810Phase 1

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed

NCT03158935Phase 1

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

Completed

NCT01355562Phase 2

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Withdrawn

NCT00697671Phase 1

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Completed

NCT00059475Phase 2

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Completed

NCT00176761Phase 2

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

Terminated

All 15 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 15